Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study

Cancer Res (2024) 84 (9_Supplement): LBO1-01.

https://doi.org/10.1158/1538-7445.SABCS23-LBO1-01

Published: 02 May 2024

View article titled, Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study

Journal Articles

Abstract PO5-25-12: CDH1 mutations predict resistance to neoadjuvant taxane therapy

Cancer Res (2024) 84 (9_Supplement): PO5-25-12.

https://doi.org/10.1158/1538-7445.SABCS23-PO5-25-12

Published: 02 May 2024

View article titled, Abstract PO5-25-12: CDH1 mutations predict resistance to neoadjuvant taxane therapy

Journal Articles

Abstract PO1-02-13: Germline mutation status of BRCA1/2 and other breast cancer predisposition genes as predictive and prognostic biomarker: Results of the GeparX study (GeparX-BRCA)

Cancer Res (2024) 84 (9_Supplement): PO1-02-13.

https://doi.org/10.1158/1538-7445.SABCS23-PO1-02-13

Published: 02 May 2024

View article titled, Abstract PO1-02-13: Germline mutation status of BRCA1/2 and other breast cancer predisposition genes as predictive and prognostic biomarker: Results of the GeparX study (GeparX-BRCA)

Journal Articles

Abstract PS14-07: Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial

Cancer Res (2024) 84 (9_Supplement): PS14-07.

https://doi.org/10.1158/1538-7445.SABCS23-PS14-07

Published: 02 May 2024

View article titled, Abstract PS14-07: Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial

Journal Articles

Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)

Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kuemmel, Carsten Denkert, Yeon Hee Park, Rina Hui, Masato Takahashi, Carlos Barrios, Yalin Zhu, Xiaoli Zhang, Wilbur Pan, Vassiliki Karantza, Joyce O'Shaughnessy, Peter Schmid

Cancer Res (2024) 84 (9_Supplement): PS14-05.

https://doi.org/10.1158/1538-7445.SABCS23-PS14-05

Published: 02 May 2024

View article titled, Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)

Journal Articles

Abstract P3-01-09: Maintenance Therapy with ET and Ribociclib after 1st line Chemotherapy (CT) in Hormone Receptor (HR)-positive/HER2-negative Metastatic Breast Cancer (BC): a Phase II Trial (AMICA)

Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, Jenny Furlanetto, Kristina Lübbe, Mark-Oliver Zahn, Marcus Schmidt, Carsten Denkert, Ralf Lorenz, Volkmar Müller, Dirk-Michael Zahm, Christoph Mundhenke, Stefan Bauer, Marc Thill, Peter Seropian, Natalie Filmann, Sibylle Loibl

Cancer Res (2023) 83 (5_Supplement): P3-01-09.

https://doi.org/10.1158/1538-7445.SABCS22-P3-01-09

Published: 01 March 2023

View article titled, Abstract P3-01-09: Maintenance Therapy with ET and Ribociclib after 1st line Chemotherapy (CT) in Hormone Receptor (HR)-positive/HER2-negative Metastatic Breast Cancer (BC): a Phase II Trial (AMICA)

Journal Articles

Abstract PD15-06: PD15-06 Pathologic complete response and breast-conserving surgery are associated with improved prognosis in patients with early-stage triple-negative breast cancer treated with neoadjuvant chemotherapy

David Krug, Valentina Vladimirova, Michael Untch, Thorsten Kühn, Andreas Schneeweiss, Carsten Denkert, Beyhan Ataseven, Christine Solbach, Bernd Gerber, Hans Tesch, Michael Golatta, Sabine Seiler, Jörg Heil, Valentina Nekljudova, Sibylle Loibl

Cancer Res (2023) 83 (5_Supplement): PD15-06.

https://doi.org/10.1158/1538-7445.SABCS22-PD15-06

Published: 01 March 2023

View article titled, Abstract PD15-06: PD15-06 Pathologic complete response and breast-conserving surgery are associated with improved prognosis in patients with early-stage triple-negative breast cancer treated with neoadjuvant chemotherapy

Journal Articles

Abstract GS5-02: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

Cancer Res (2023) 83 (5_Supplement): GS5-02.

https://doi.org/10.1158/1538-7445.SABCS22-GS5-02

Published: 01 March 2023

View article titled, Abstract GS5-02: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

Journal Articles

Abstract PD4-02: PD4-02 Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy

Cancer Res (2023) 83 (5_Supplement): PD4-02.

https://doi.org/10.1158/1538-7445.SABCS22-PD4-02

Published: 01 March 2023

View article titled, Abstract PD4-02: PD4-02 Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy

Journal Articles

Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

Heather McArthur, Javier Cortés, Rebecca Dent, Joyce O’Shaughnessy, Lajos Pusztai, Sherko Küemmel, Theodoros Foukakis, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Carsten Denkert, Yalin Zhu, Yu Ding, Wilbur Pan, Peter Schmid

Cancer Res (2023) 83 (5_Supplement): PD3-01.

https://doi.org/10.1158/1538-7445.SABCS22-PD3-01

Published: 01 March 2023

View article titled, Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

Journal Articles

Abstract P4-06-13: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

Cancer Res (2023) 83 (5_Supplement): P4-06-13.

https://doi.org/10.1158/1538-7445.SABCS22-P4-06-13

Published: 01 March 2023

View article titled, Abstract P4-06-13: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

Journal Articles

Abstract P2-03-23: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry

Wolfgang D. Schmitt, Paul Jank, Inga Hoffmann, Berit M. Pfitzner, Lauren Lenz, Wyatt Clegg, Elke Keil, Sarah Ratzel, Elizabeth S. Cogan, Jens-Uwe Blohmer, Pauline Wimberger, Ralf Kronenwett, David Horst, Carsten Denkert

Cancer Res (2023) 83 (5_Supplement): P2-03-23.

https://doi.org/10.1158/1538-7445.SABCS22-P2-03-23

Published: 01 March 2023

View article titled, Abstract P2-03-23: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry

Journal Articles

Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping

Cancer Res (2023) 83 (5_Supplement): HER2-06.

https://doi.org/10.1158/1538-7445.SABCS22-HER2-06

Published: 01 March 2023

View article titled, Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping

Journal Articles

Abstract PD17-06: Immunohistochemical markers and determinants of clinical response in the Penelope-B trial

Cancer Res (2023) 83 (5_Supplement): PD17-06.

https://doi.org/10.1158/1538-7445.SABCS22-PD17-06

Published: 01 March 2023

View article titled, Abstract PD17-06: Immunohistochemical markers and determinants of clinical response in the Penelope-B trial

Journal Articles

Abstract PD17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials

Cancer Res (2023) 83 (5_Supplement): PD17-05.

https://doi.org/10.1158/1538-7445.SABCS22-PD17-05

Published: 01 March 2023

View article titled, Abstract PD17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials

Journal Articles

Abstract PD9-04: Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients

Cancer Res (2023) 83 (5_Supplement): PD9-04.

https://doi.org/10.1158/1538-7445.SABCS22-PD9-04

Published: 01 March 2023

View article titled, Abstract PD9-04: Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients

Journal Articles

Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

Cancer Res (2022) 82 (7): 1321–1339.

https://doi.org/10.1158/0008-5472.CAN-21-2576

Published: 01 April 2022

View article titled, Hotspot <em>ESR1</em> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

Includes: Supplementary data

Journal Articles

Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study

Cancer Res (2022) 82 (4_Supplement): P5-13-36.

https://doi.org/10.1158/1538-7445.SABCS21-P5-13-36

Published: 15 February 2022

View article titled, Abstract P5-13-36: Germline <em>BRCA</em>1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study

Journal Articles

Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

Cancer Res (2022) 82 (4_Supplement): PD2-04.

https://doi.org/10.1158/1538-7445.SABCS21-PD2-04

Published: 15 February 2022

View article titled, Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

Journal Articles

Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer

Anja Kathrin Wege, Valentina Vladimirova, Christine Solbach, Eva-Maria Rom-Jurek, Jens-Uwe Blohmer, Paul Jank, Bruno Sinn, Andreas Trumpp, Elisabetta Marangoni, Knut Engels, Wilko Weichert, Nicole Pfarr, Christoph Irlbeck, Bernhard Polzer, Olaf Ortmann, Marion van Mackelenbergh, Carsten Denkert, Sibylle Loibl, Gero Brockhoff

Cancer Res (2022) 82 (4_Supplement): PD9-07.

https://doi.org/10.1158/1538-7445.SABCS21-PD9-07

Published: 15 February 2022

View article titled, Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer

NARROW

Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study

Abstract PO5-25-12: CDH1 mutations predict resistance to neoadjuvant taxane therapy

Abstract PO1-02-13: Germline mutation status of BRCA1/2 and other breast cancer predisposition genes as predictive and prognostic biomarker: Results of the GeparX study (GeparX-BRCA)

Abstract PS14-07: Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial

Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)

Abstract P3-01-09: Maintenance Therapy with ET and Ribociclib after 1st line Chemotherapy (CT) in Hormone Receptor (HR)-positive/HER2-negative Metastatic Breast Cancer (BC): a Phase II Trial (AMICA)

Abstract PD15-06: PD15-06 Pathologic complete response and breast-conserving surgery are associated with improved prognosis in patients with early-stage triple-negative breast cancer treated with neoadjuvant chemotherapy

Abstract GS5-02: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

Abstract PD4-02: PD4-02 Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy

Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

Abstract P4-06-13: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

Abstract P2-03-23: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry

Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping

Abstract PD17-06: Immunohistochemical markers and determinants of clinical response in the Penelope-B trial

Abstract PD17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials

Abstract PD9-04: Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients

Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study

Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only